Related Experiment Video
Updated: May 5, 2026
Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody mAb by Neutralizing TNF Using an In Vitro Bioanalytical Method
Published on: September 16, 2017
Antibody against tumor necrosis factor-α reduces bortezomib-induced allodynia in a rat model
Alessia Chiorazzi1, Annalisa Canta, Cristina Meregalli
1University of Milano Bicocca, via Cadore 48, 20900 Monza (MB), Italy. alessia.chiorazzi@unimib.it.
Background:
Bortezomib is an anti-neoplastic drug acting against multiple myeloma but its use is associated with the onset of painful peripheral neuropathy. Tumor necrosis factor-α (TNFα) is associated with the development of neuropathic pain; several models have shown that the inactivation of TNFα leads to a reduction in pain stimuli perception. The aim of the present study was to analyze if the administration of an antibody against TNFα is able to prevent the development of bortezomib-induced neuropathic pain.
Materials And Methods:
Nerve conduction velocity was measured and a histopathological examination was performed to assess the extent of peripheral neuropathy. To study the onset of painful neuropathy, the response to mechanical or thermal stimuli was evaluated.
Results:
This study demonstrated that co-administration of an antibody against TNFα is able to prevent allodynia induced by bortezomib but does not reduce neuropathy.
Conclusion:
Targeting TNFα might be useful in limiting patients' discomfort during bortezomib therapy.
Insights
An antibody targeting Tumor Necrosis Factor-alpha (TNFα) prevented pain in bortezomib-treated patients but did not reduce nerve damage. This suggests TNFα inhibition may alleviate bortezomib-induced neuropathic pain.
Area of Science:
- Neuroscience
- Pharmacology
- Oncology
Background:
- Bortezomib is a multiple myeloma treatment causing painful peripheral neuropathy.
- Tumor Necrosis Factor-alpha (TNFα) is implicated in neuropathic pain development.
- Inhibiting TNFα has shown potential in reducing pain perception.
Purpose of the Study:
- To investigate if an antibody against TNFα can prevent bortezomib-induced neuropathic pain.
- To evaluate the efficacy of TNFα targeting in managing bortezomib side effects.
Main Methods:
- Assessed nerve conduction velocity and performed histopathological examination.
- Evaluated responses to mechanical and thermal stimuli to study neuropathic pain onset.
Main Results:
- Co-administration of a TNFα antibody prevented bortezomib-induced allodynia.
- The antibody treatment did not reduce the extent of peripheral neuropathy.
Conclusions:
- Targeting TNFα may be beneficial in managing patient discomfort during bortezomib therapy.
- TNFα inhibition shows promise for alleviating pain associated with bortezomib treatment.
More Related Videos
09:27Cell Subtype-specific Analysis of Neuronal Membrane Proteasome in Somatosensory Neurons
Published on: October 10, 2025
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019